Gaylyn Horne, MD
Pain Medicine · Pell City, ALNPI 1750331542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $276 and has fallen 53.7% since, to $128 in 2025. That places this record below the midpoint for pain medicine clinicians in AL, where the typical reported total is $1,761.
Across 47 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$136
- AbbVie$109
- Pfizer$84
- Daiichi Sankyo Inc.$70
- Lilly USA, LLC$53
- Novo Nordisk$53
- plus $353 from 17 others
What the payments were for
- Food & beverage$859100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 9 | $136 |
| AbbVie | 4 | $109 |
| Pfizer | 5 | $84 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Lilly USA, LLC | 3 | $53 |
| Novo Nordisk | 3 | $53 |
| Boston Scientific | 2 | $41 |
| CSL Behring | 1 | $37 |
| Amgen | 2 | $32 |
| Biodelivery Sciences International, Inc. | 2 | $30 |
| Medtronic | 1 | $29 |
| Novartis | 1 | $24 |
| Merck | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Saluda Medical Americas, Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sentynl Therapeutics, Inc. | 1 | $12 |
| Si-bone, Inc. | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
How this compares
$859 in reported general payments places this provider in the 40th percentile of 77 pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 254 | $83,802 |
| Xtampza ErOxycodone Myristate | 128 | $67,256 |
| MounjaroTirzepatide | 58 | $60,591 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,336 | $59,038 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,935 | $48,548 |
| BelbucaBuprenorphine Hcl | 46 | $44,536 |
| LinzessLinaclotide | 77 | $42,372 |
| OxycontinOxycodone Hcl | 64 | $36,682 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 128 | $31,941 |
| OzempicSemaglutide | 34 | $31,865 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $26,060 |
| Gabapentin | 2,015 | $22,457 |
| Buprenorphine Hcl | 351 | $21,676 |
| MovantikNaloxegol Oxalate | 43 | $18,618 |
| Pregabalin | 693 | $15,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er | $136 | $119,120185 claims |
| Lilly USA, LLCMounjaro | $53 | $60,59158 claims |
| Novo NordiskOzempic, Rybelsus | $53 | $45,09348 claims |
| AbbVieLinzess | $109 | $42,37277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 77 pain medicine providers in Alabama.
Other pain medicine in Pell City
- Christopher PaulBirmingham$64K
- Michael CosgroveHuntsville$25K
- Ron PitkanenMountain Brk$16K
- Elliott PenningtonDaphne$15K
- James ThackerHuntsville$13K
- Grant StoneMobile$11K
- Hayden HundleyDothan$11K
- Hugh MaddoxAnniston$10K
- Jeremy BarlowVestavia Hills$9K
- Nitin ChhabraHoover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.